Article Details
Retrieved on: 2024-07-09 21:40:05
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In light of AEON Biopharma's strategic pivot to pursue a biosimilar pathway for its ABP-450 drug candidate, current and prospective investors may find ...
Article found on: www.investing.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here